PET/MRI in infectious and inflammatory diseases: Will it be a useful improvement?

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 39, Issue 5, 2012, Pages 745-749

  Glaudemans, Andor W J M ^a   Quintero, Ana Maria ^b   Signore, Alberto ^a,c,d  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b Department of Radiology   (Colombia)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

8 QUINOLINOL INDIUM IN 111; FLUORODEOXYGLUCOSE F 18; HEXAMETHYLPROPYLENE AMINE OXIME TECHNETIUM TC 99M; N (4 [18F] FLUOROBENZYL)INTERLEUKIN 2; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

COMPUTER ASSISTED EMISSION TOMOGRAPHY; COST BENEFIT ANALYSIS; DIABETIC FOOT; DIAGNOSTIC ACCURACY; DIFFUSION WEIGHTED IMAGING; EDITORIAL; ENTERITIS; FOLLOW UP; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; INFECTION; INFLAMMATORY DISEASE; INSULIN DEPENDENT DIABETES MELLITUS; INTERVERTEBRAL DISK DEGENERATION; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; POSITRON EMISSION TOMOGRAPHY; SENSITIVITY AND SPECIFICITY;

COST-BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 1; DIABETIC FOOT; DISCITIS; HUMANS; INFECTION; INFLAMMATION; INFLAMMATORY BOWEL DISEASES; MAGNETIC RESONANCE IMAGING; POSITRON-EMISSION TOMOGRAPHY;

EID: 84862582911     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-012-2060-9     Document Type: Editorial

References (26)

1. Achenbach P, Bonifacio E, Koczwara K, Ziegler AG. Natural history of type 1 diabetes. Diabetes. 2005;54 Suppl 2:S25-31.
2. Nichols MT, Russ PD, Chen YK. Pancreatic imaging: current and emerging technologies. Pancreas. 2006;33:211-20.
3. Gaglia JL, Guimaraes AR, Harisinghani M, Turvey SE, Jackson R, Benoist C, et al. Noninvasive imaging of pancreatic islet inflammation in type 1A diabetes patients. J Clin Invest. 2011;121:442-5.
4. Barone R, Procaccini E, Chianelli M, Annovazzi A, Fiore V, Hawa M, et al. Prognostic relevance of pancreatic uptake of technetium-99m labelled human polyclonal immunoglobulins in patients with type 1 diabetes. Eur J Nucl Med. 1998;25:503-8.
5. Kalliokoski T, Simell O, Haaparanta M, Viljanen T, Solin O, Knuuti J, et al. An autoradiographic study of [(18)F]FDG uptake to islets of Langerhans in NOD mouse. Diabetes Res Clin Pract. 2005;70:217-24.
6. Kalliokoski T, Nuutila P, Virtanen KA, Iozzo P, Bucci M, Svedström E, et al. Pancreatic glucose uptake in vivo in men with newly diagnosed type 1 diabetes. J Clin Endocrinol Metab. 2008;93:1909-14.
7. Ladriere L, Malaisse-Lagae F, Alejandro R, Malaisse WJ. Pancreatic fate of a (125)I-labelled mouse monoclonal antibody directed against pancreatic B-cell surface ganglioside(s) in control and diabetic rats. Cell Biochem Funct. 2001;19:107-15.
8. Malaisse WJ, Damhaut P, Malaisse-Lagae F, Ladriere L, Olivares E, Goldman S. Fate of 2-deoxy-2-[18F]fluoro-D-glucose in control and diabetic rats. Int J Mol Med. 2000;5:525-32.
9. Signore A, Chianelli M, Parisella MG, Capriotti G, Giacalone P, Di LG, et al. In vivo imaging of insulitis in autoimmune diabetes. J Endocrinol Invest. 1999;22:151-8.
10. Chianelli M, Parisella MG, Visalli N, Mather SJ, D'Alessandria C, Pozzilli P, et al. Pancreatic scintigraphy with 99mTc-interleukin-2 at diagnosis of type 1 diabetes and after 1 year of nicotinamide therapy. Diabetes Metab Res Rev. 2008;24:115-22.
11. Signore A, Chianelli M, Ronga G, Pozzilli P, Beverley PC. In vivo labelling of activated T lymphocytes by i.v. injection of 123I-IL2 for detection of insulitis in type 1 diabetes. Prog Clin Biol Res. 1990;355:229-38.
12. Signore A, Chianelli M, Ferretti E, Toscano A, Britton KE, Andreani D, et al. New approach for in vivo detection of insulitis in type I diabetes: activated lymphocyte targeting with 123Ilabelled interleukin 2. Eur J Endocrinol. 1994;131:431-7.
13. Sobottke R, Rollinghoff M, Zarghooni K, Zarghooni K, Schluter-Brust K, Delank KS, et al. Spondylodiscitis in the elderly patient: clinical mid-term results and quality of life. Arch Orthop Trauma Surg. 2010;130:1083-91.
14. Gouliouris T, Aliyu SH, Brown NM. Spondylodiscitis: update on diagnosis and management. J Antimicrob Chemother. 2010;65 Suppl 3:iii11-24.
15. Verstraete KL, Huysse WC. Health technology assessment of magnetic resonance imaging of the spine and bone marrow. Eur J Radiol. 2008;65:201-10.
16. Loftus Jr EV. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology. 2004;126:1504-17.
17. Maccioni F, Bruni A, Viscido A, Colaiacomo MC, Cocco A, Montesani C, et al. MR imaging in patients with Crohn disease: value of T2-versus T1-weighted gadolinium-enhanced MR sequences with use of an oral superparamagnetic contrast agent. Radiology. 2006;238:517-30.
18. Glaudemans AW, Maccioni F, Mansi L, Dierckx RA, Signore A. Imaging of cell trafficking in Crohn's disease. J Cell Physiol. 2010;223:562-71.
19. Rimola J, Rodriguez S, Garcia-Bosch O, Ordas I, Ayala E, Aceituno M, et al. Magnetic resonance for assessment of disease activity and severity in ileocolonic Crohn's disease. Gut. 2009;58:1113-20.
20. Golder W. Magnetic resonance spectroscopy in clinical oncology. Onkologie. 2004;27:304-9.
21. Kiryu S, Dodanuki K, Takao H,Watanabe M, Inoue Y, Takazoe M, et al. Free-breathing diffusion-weighted imaging for the assessment of inflammatory activity in Crohn's disease. J Magn Reson Imaging. 2009;29:880-6.
22. Cassidy PJ, Radda GK. Molecular imaging perspectives. J R Soc Interface. 2005;2:133-44.
23. Capriotti G, Chianelli M, Signore A. Nuclear medicine imaging of diabetic foot infection: results of meta-analysis. Nucl Med Commun. 2006;27:757-64.
24. de Vries EF, Roca M, Jamar F, Israel O, Signore A. Guidelines for the labelling of leucocytes with (99m)Tc-HMPAO. Inflammation/ Infection Taskgroup of the European Association of Nuclear Medicine. Eur J Nucl Med Mol Imaging. 2010;37:842-8.
25. Roca M, de Vries EF, Jamar F, Israel O, Signore A. Guidelines for the labelling of leucocytes with (111)In-oxine. Inflammation/Infection Taskgroup of the European Association of Nuclear Medicine. Eur J Nucl Med Mol Imaging. 2010;37:835-41.
26. Familiari D, Glaudemans AW, Vitale V, Prosperi D, Bagni O, Lenza A, et al. Can sequential 18F-FDG PET/CT replace WBC imaging in the diabetic foot? J Nucl Med. 2011;52:1012-9.